BioVersys and Shionogi are joining forces to progress the development of non-tuberculous mycobacteria clinical candidates with the potential for a selected number of molecules to be licensed for global commercialization.

The collaboration will leverage Bend’s expertise in controlled release formulation, manufacturing process, and analytical method development, and Starton’s deep understanding of continuous delivery of lenalidomide.

The companies will combine a drug discovery platform and a novel framework to reduce the cost and time it takes to develop complex therapies.

The proposed acquisition will expand Sanofi’s immunological portfolio with a precision medicine already approved for the treatment of ASM and ISM, a next-gen highly selective kinase inhibitor, and an investigational oral drug.

Porton Advanced has announced separate partnerships with TongEYE and Hualong Biological, as it moves into regenerative therapies for vision loss and innovative immunotherapies for solid tumors.

The court supervised purchase, which is still subject to relevant conditions, will see Regeneron acquire the assets of 23andMe, except for its Lemonaid Health business.

The acquisition of efimosfermin alfa, a Phase III-ready FGF21 analog targeting steatotic liver diseases, will expand GSK’s hepatology pipeline and establish a best-in-class therapy for MASH and ALD.

Through this sizable acquisition, Merck will accelerate its growth in the rare tumor segment and boost its U.S. oncology presence.

Pharmaceutical company, Granules India, has acquired Swiss CDMO, Senn Chemicals AG, for CHF 20 million (USD22 million) through its subsidiary, Granules Peptides as it enters the peptide therapeutics sector.

The radiopharmaceuticals CDMO will have a majority stake in Agilera Pharma, advancing its strategy of becoming a fully-integrated service provider in the radiopharmaceutical therapy sector.

Drug delivery companies — SHL Medical and Kindeva Drug Delivery — have formed a partnership to enhance SHL Medical’s Molly® autoinjector platform aimed at pharmaceutical and biotechnology companies.

Advanced therapy medicinal products specialist CDMO, Porton Advanced, and clinical-stage biotech, Eureka Therapeutics, have entered a strategic collaboration to accelerate the development and commercialization of T-cell therapies for cancer treatment.

Curium, a global leader in nuclear medicine, has announced the acquisition of radiopharmaceutical company, Monrol, as the company aims to improve its position in the global nuclear medicine market,.

Novo Nordisk has entered into an exclusive global licensing agreement with Lexicon Pharmaceuticals for Lexicon’s promising drug candidate, LX9851, which targets gastrointestinal disorders.

US CDMO, Bionova Scientific, has selected New York CRO, Bionique Testing Laboratories, as its preferred provider for mycoplasma testing services in biologics manufacturing. The appointment will allow enhanced quality control processes for biologics production, ensuring the safety and efficacy of therapeutic products.

Minneapolis-based drug development company, Humanetics Corporation, with funding support from the U.S. Department of Defense, has engaged Lifecore Biomedical to provide CDMO services for BIO 300, a novel radioprotective agent aimed at preventing acute radiation syndrome.

Korean CDMO, ENCell, has signed a Memorandum of Understanding (MOU) with Japan's Cell Resources Corporation (CRC) to expand its presence in the Japanese cell and gene therapy market.

Full-service CDMO, CordenPharma, and clinical-stage biopharmaceutical company, Viking Therapeutics, have entered a multi-year strategic partnership to support the development and commercialization of Viking's GLP-1 drug candidate, VK2735.

Synthetic biology company, Asimov, and Korean manufacturer, Lotte Biologics, have formed a partnership to streamline the transition from cell line development to large-scale GMP production. This collaboration integrates Asimov's CHO Edge platform - known for generating high-titer, stable cell lines - with Lotte Biologics' extensive manufacturing capabilities.

Summit Therapeutics has announced a clinical trial collaboration with Pfizer to assess a novel investigational PD-1/VEGF bispecific antibody, ivonescimab, in combination with Pfizer's antibody-drug conjugates across various solid tumor settings.